At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Spesolimab (low dose) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)
In Brief
A Phase 2 clinical trial evaluating Spesolimab (low dose), Placebo, and 1 other intervention for Psoriasis. Completed, enrolled 59 participants across 18 sites in 6 countries.
Detailed Summary
The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, Denmark, Germany, Italy, Spain, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartMay 2017
Primary CompletionJul 2018
Study CompletionNov 2018
TodayJul 2026
First PostedMay 1, 2017
Enrollment StartMay 30, 2017
Primary CompletionJul 12, 2018
Study CompletionNov 14, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.2 years ago
Interventions
Spesolimab (low dose)drug
12 weeks treatment
Placebodrug
12 weeks treatment
Spesolimab (high dose)drug
12 weeks treatment